Global Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Regional Outlook and Forecast, 2022 - 2028

Global Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Regional Outlook and Forecast, 2022 - 2028

The Global Neurological Biomarkers Market size is expected to reach $12.9 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.

The term "biomarker," a portmanteau of "biological marker," refers to a large subclass of medical signs, or objective indicators of health status seen from the outside of the patient, which can be quantified precisely and consistently. Medical symptoms, on the other hand, are only those markers of health or disease that patients themselves may perceive. The literature contains several more detailed definitions of biomarkers, and they have a lot in common.

A biomarker is "a characteristic that is measured and evaluated objectively as an indicator of normal biochemical functions, pathogenic processes, or pharmacologic responses to a therapeutic intervention," according to the National Institutes of Health Biomarkers Definitions Working Group definition from 1998.

The World Health Organization (WHO), in collaboration with the United Nations and the International Labor Organization, established the International Program on Chemical Safety, which defines a biomarker as "any substance, structure, or procedure that can be evaluated in the body or its product lines and influence or predict the incidence of outcome or disease.

A definition that goes even further considers not only the occurrence and course of a disease, but also its treatment, interventions, and even inadvertent environmental exposure to substances like toxins or nutrients. Before the invention of better technology, it was difficult for researchers to monitor brain health by analyzing molecules since there were so few biomarkers for neurological illnesses. This entails less invasive testing, quicker medication development, earlier diagnosis, and hopefully more efficient therapies.

COVID-19 Impact Analysis

Almost every business has been impacted by the unmatched worldwide public health emergency known as COVID-19, and the long-term impacts are expected to influence industry growth throughout the course of the forecast period. According to research by Diaceutics PLC (UK) on the diagnosis and biomarker testing rates for various cancer types, the number of newly diagnosed patients with metastatic non-small cell lung cancer decreased between February 2020 and March 2020. The rates of KRAS, BRAF, and EGFR testing, which are important indicators supporting the optimal choice of precision medicine medicines that benefit particular patients, were also significantly influenced by this abrupt decline in just one month.

Market Growth Factor

Companion Diagnostics Are Becoming More Important

In the practice of medicine, companion diagnostics and biomarkers are becoming more and more important, which has enhanced disease-specific diagnosis, therapy, and monitoring. It can be used to identify patients who will likely respond well to specific treatments or drugs. These diagnostics frequently go hand in hand with certain medicine.

The Growing Concept of Individual Medicine

In customized medicine, biomarkers are crucial because they can be used for diagnosis, prognosis, and choosing specific treatments. Personalized medicine has grown in popularity over time as a result of the different drawbacks of conventional methods for diagnosis and treatment. Numerous medical specialties from cancer to immunological disorders are moving toward individualized patient care based on their genetic profiles and phenotypic traits.

Market Restraining Factor

High Startup Costs and Protracted Biomarker Development Cycles

Due to the variability in how well they perform in illness detection, evaluating biomarkers is a time-consuming process. As a result, the validation procedure grows expensive and time-consuming. The process and timetable for developing and validating biomarkers are therefore comparable across biomarker categories, with a few exceptions, because different categories of biomarkers frequently share common development and validation process phases.

Type Outlook

Based on the Type, the Neurological Biomarkers Market is segmented into Genomic, Proteomic, Metabolomic, and Others. The genomic segment acquired a significant revenue share in the neurological biomarkers market in 2021. Increased prevalence of neurological disorders, an increase in the estimated incidence of ischemic stroke, elevated demand for minimally procedures, technological advancements in clinical laboratory tests and rising public awareness of genomic biomarker-based personalized medicines are all contributing factors to the expansion of the genomic biomarkers market.

Application Outlook

On the basis of Application, the Neurological Biomarkers Market is divided into Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis. The Alzheimer’s disease segment procured the largest revenue share in the neurological biomarkers market in 2021. due to an increase in clinical trials, research, and drug development as well as an increase in the prevalence of Alzheimer's disease. Drug development for Alzheimer's disease (AD) heavily relies on biomarkers.

Regional Outlook

Region-wise, the Neurological Biomarkers Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the highest revenue share in the neurological biomarkers market in 2021. The increase in American studies suggests a decrease in the age-specific risk of Alzheimer's disease and other forms of dementia in the United States and other high-income western nations over the previous 25 years.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Proteomic
  • Genomic
  • Metabolomic
  • Others
By Application
  • Alzheimer's Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • F. HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • Merck Group
  • PERKINELMER INC.
  • Shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix Corporation
  • Neuro-Bio Ltd.
  • BioMérieux S.A.
  • Myriad Genetics, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Neurological Biomarkers Market, by Type
1.4.2 Global Neurological Biomarkers Market, by Application
1.4.3 Global Neurological Biomarkers Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Neurological Biomarkers Market by Type
3.1 Global Proteomic Market by Region
3.2 Global Genomic Market by Region
3.3 Global Metabolomic Market by Region
3.4 Global Others Market by Region
Chapter 4. Global Neurological Biomarkers Market by Application
4.1 Global Alzheimer's Disease Market by Region
4.2 Global Parkinson’s Disease Market by Region
4.3 Global Multiple Sclerosis Market by Region
Chapter 5. Global Neurological Biomarkers Market by Region
5.1 North America Neurological Biomarkers Market
5.1.1 North America Neurological Biomarkers Market by Type
5.1.1.1 North America Proteomic Market by Country
5.1.1.2 North America Genomic Market by Country
5.1.1.3 North America Metabolomic Market by Country
5.1.1.4 North America Others Market by Country
5.1.2 North America Neurological Biomarkers Market by Application
5.1.2.1 North America Alzheimer's Disease Market by Country
5.1.2.2 North America Parkinson’s Disease Market by Country
5.1.2.3 North America Multiple Sclerosis Market by Country
5.1.3 North America Neurological Biomarkers Market by Country
5.1.3.1 US Neurological Biomarkers Market
5.1.3.1.1 US Neurological Biomarkers Market by Type
5.1.3.1.2 US Neurological Biomarkers Market by Application
5.1.3.2 Canada Neurological Biomarkers Market
5.1.3.2.1 Canada Neurological Biomarkers Market by Type
5.1.3.2.2 Canada Neurological Biomarkers Market by Application
5.1.3.3 Mexico Neurological Biomarkers Market
5.1.3.3.1 Mexico Neurological Biomarkers Market by Type
5.1.3.3.2 Mexico Neurological Biomarkers Market by Application
5.1.3.4 Rest of North America Neurological Biomarkers Market
5.1.3.4.1 Rest of North America Neurological Biomarkers Market by Type
5.1.3.4.2 Rest of North America Neurological Biomarkers Market by Application
5.2 Europe Neurological Biomarkers Market
5.2.1 Europe Neurological Biomarkers Market by Type
5.2.1.1 Europe Proteomic Market by Country
5.2.1.2 Europe Genomic Market by Country
5.2.1.3 Europe Metabolomic Market by Country
5.2.1.4 Europe Others Market by Country
5.2.2 Europe Neurological Biomarkers Market by Application
5.2.2.1 Europe Alzheimer's Disease Market by Country
5.2.2.2 Europe Parkinson’s Disease Market by Country
5.2.2.3 Europe Multiple Sclerosis Market by Country
5.2.3 Europe Neurological Biomarkers Market by Country
5.2.3.1 Germany Neurological Biomarkers Market
5.2.3.1.1 Germany Neurological Biomarkers Market by Type
5.2.3.1.2 Germany Neurological Biomarkers Market by Application
5.2.3.2 UK Neurological Biomarkers Market
5.2.3.2.1 UK Neurological Biomarkers Market by Type
5.2.3.2.2 UK Neurological Biomarkers Market by Application
5.2.3.3 France Neurological Biomarkers Market
5.2.3.3.1 France Neurological Biomarkers Market by Type
5.2.3.3.2 France Neurological Biomarkers Market by Application
5.2.3.4 Russia Neurological Biomarkers Market
5.2.3.4.1 Russia Neurological Biomarkers Market by Type
5.2.3.4.2 Russia Neurological Biomarkers Market by Application
5.2.3.5 Spain Neurological Biomarkers Market
5.2.3.5.1 Spain Neurological Biomarkers Market by Type
5.2.3.5.2 Spain Neurological Biomarkers Market by Application
5.2.3.6 Italy Neurological Biomarkers Market
5.2.3.6.1 Italy Neurological Biomarkers Market by Type
5.2.3.6.2 Italy Neurological Biomarkers Market by Application
5.2.3.7 Rest of Europe Neurological Biomarkers Market
5.2.3.7.1 Rest of Europe Neurological Biomarkers Market by Type
5.2.3.7.2 Rest of Europe Neurological Biomarkers Market by Application
5.3 Asia Pacific Neurological Biomarkers Market
5.3.1 Asia Pacific Neurological Biomarkers Market by Type
5.3.1.1 Asia Pacific Proteomic Market by Country
5.3.1.2 Asia Pacific Genomic Market by Country
5.3.1.3 Asia Pacific Metabolomic Market by Country
5.3.1.4 Asia Pacific Others Market by Country
5.3.2 Asia Pacific Neurological Biomarkers Market by Application
5.3.2.1 Asia Pacific Alzheimer's Disease Market by Country
5.3.2.2 Asia Pacific Parkinson’s Disease Market by Country
5.3.2.3 Asia Pacific Multiple Sclerosis Market by Country
5.3.3 Asia Pacific Neurological Biomarkers Market by Country
5.3.3.1 China Neurological Biomarkers Market
5.3.3.1.1 China Neurological Biomarkers Market by Type
5.3.3.1.2 China Neurological Biomarkers Market by Application
5.3.3.2 Japan Neurological Biomarkers Market
5.3.3.2.1 Japan Neurological Biomarkers Market by Type
5.3.3.2.2 Japan Neurological Biomarkers Market by Application
5.3.3.3 India Neurological Biomarkers Market
5.3.3.3.1 India Neurological Biomarkers Market by Type
5.3.3.3.2 India Neurological Biomarkers Market by Application
5.3.3.4 Australia Neurological Biomarkers Market
5.3.3.4.1 Australia Neurological Biomarkers Market by Type
5.3.3.4.2 Australia Neurological Biomarkers Market by Application
5.3.3.5 South Korea Neurological Biomarkers Market
5.3.3.5.1 South Korea Neurological Biomarkers Market by Type
5.3.3.5.2 South Korea Neurological Biomarkers Market by Application
5.3.3.6 Singapore Neurological Biomarkers Market
5.3.3.6.1 Singapore Neurological Biomarkers Market by Type
5.3.3.6.2 Singapore Neurological Biomarkers Market by Application
5.3.3.7 Rest of Asia Pacific Neurological Biomarkers Market
5.3.3.7.1 Rest of Asia Pacific Neurological Biomarkers Market by Type
5.3.3.7.2 Rest of Asia Pacific Neurological Biomarkers Market by Application
5.4 LAMEA Neurological Biomarkers Market
5.4.1 LAMEA Neurological Biomarkers Market by Type
5.4.1.1 LAMEA Proteomic Market by Country
5.4.1.2 LAMEA Genomic Market by Country
5.4.1.3 LAMEA Metabolomic Market by Country
5.4.1.4 LAMEA Others Market by Country
5.4.2 LAMEA Neurological Biomarkers Market by Application
5.4.2.1 LAMEA Alzheimer's Disease Market by Country
5.4.2.2 LAMEA Parkinson’s Disease Market by Country
5.4.2.3 LAMEA Multiple Sclerosis Market by Country
5.4.3 LAMEA Neurological Biomarkers Market by Country
5.4.3.1 Brazil Neurological Biomarkers Market
5.4.3.1.1 Brazil Neurological Biomarkers Market by Type
5.4.3.1.2 Brazil Neurological Biomarkers Market by Application
5.4.3.2 Argentina Neurological Biomarkers Market
5.4.3.2.1 Argentina Neurological Biomarkers Market by Type
5.4.3.2.2 Argentina Neurological Biomarkers Market by Application
5.4.3.3 UAE Neurological Biomarkers Market
5.4.3.3.1 UAE Neurological Biomarkers Market by Type
5.4.3.3.2 UAE Neurological Biomarkers Market by Application
5.4.3.4 Saudi Arabia Neurological Biomarkers Market
5.4.3.4.1 Saudi Arabia Neurological Biomarkers Market by Type
5.4.3.4.2 Saudi Arabia Neurological Biomarkers Market by Application
5.4.3.5 South Africa Neurological Biomarkers Market
5.4.3.5.1 South Africa Neurological Biomarkers Market by Type
5.4.3.5.2 South Africa Neurological Biomarkers Market by Application
5.4.3.6 Nigeria Neurological Biomarkers Market
5.4.3.6.1 Nigeria Neurological Biomarkers Market by Type
5.4.3.6.2 Nigeria Neurological Biomarkers Market by Application
5.4.3.7 Rest of LAMEA Neurological Biomarkers Market
5.4.3.7.1 Rest of LAMEA Neurological Biomarkers Market by Type
5.4.3.7.2 Rest of LAMEA Neurological Biomarkers Market by Application
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings